Bibliography
- Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol 2008;28:317-27
- Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-9
- Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008;22:739-60
- Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005;4:571-81
- Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-44
- Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-93
- Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006;1:289-99
- Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000;356:1339-43
- Arif H, Buchsbaum R, Weintraub D, Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9
- Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:1360-5
- Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007;27:1425-39
- Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S
- Chung WH, Hung SI, Yang JY, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-50
- Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. J Neurology 2005;64:1134-8
- Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. Personalized Med 2005;2:225-37
- Mockenhaupt M, Viboud C, Dunant A, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44
- Amann B, Grunze H, Vieta E, Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci 2007;38:116-23
- Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008;24(Suppl 1):S52-7
- Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-8
- Farkas R, Clinical review, adverse events of carbamazepine. 2009 Available from URL: http://www.fda.gov/cder/foi/nda/2007/016608s098,020712s029,021710_ClinRev.pdf
- Chung WH, Hung SI, Hong HS, Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:86
- Hung SI, Chung WH, Jee SH, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306
- Man CB, Kwan P, Baum L, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-8
- Locharernkul C, Loplumlert J, Limotai C, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-91
- Chang CC, Too CL, Murad S, Hussein S. Association of HLA-B*1502 with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in Malaysian population. Proceeding in 7th Asian- Oceanian Epilepsy Congress, Xiamen; 2008
- Kaniwa N, Saito Y, Aihara M, ; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-22
- Lonjou C, Thomas L, Borot N, ; RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6:265-8
- Lonjou C, Borot N, Sekula P, ; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107
- Alfirevic A, Jorgensen AL, Williamson PR, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8
- Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005;6:241-6
- Website: Allele Frequencies. Available from: http://www.allelefrequencies.net/
- Hung SI, Chung WH, Chen YT. Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor, Drug Hypersensitivity. Karger, Medical and Scientific Publishers. Bern, Switzerland; 2007. p. 55-64
- Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7:317-23
- FDA ALERT: Dangerous or even fatal skin reactions - carbamazepine (marketed as carbatrol, equetro, tegretol, and generics) - healthcare professional sheet text version. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm
- Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-6
- Romano A, Guéant-Rodriguez RM, Viola M, Cross-reactivity among drugs: clinical problems. Toxicology 2005;209:169-79
- Romano A, Pettinato R, Andriolo M, Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006;12:3373-81
- Hirsch LJ, Arif H, Nahm EA, Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008;71:1527-34
- Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008;80:194-200
- Seitz CS, Pfeuffer P, Raith P, Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. Ann Allergy Asthma Immunol 2006;97:698-702
- Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol 2009;23:702-3
- Lin LC, Lai PC, Yang SF, Yang RC. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J Med Sci 2009;25:82-6
- Kazeem GR, Cox C, Aponte J, High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009;19:661-5